MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
Open accessAbstract
BACKGROUND & AIMS: Diagnostic criteria for metabolic associated fatty liver disease (MAFLD) have been proposed, but not validated. We aimed to compare the diagnostic accuracy of the MAFLD definition vs the existing NAFLD criteria to identify patients with significant fibrosis and to characterize the impact of mild alcohol intake. METHODS: We enrolled 765 Japanese patients with fatty liver (median age 54 years). MAFLD and NAFLD were diagnosed in 79.6% and 70.7% of patients respectively. Significant fibrosis was defined by FIB-4 index ≥1.3 and liver stiffness ≥6.6 kPa using shear wave elastography. Mild alcohol intake was defined as <20 g/day. Factors associated with significant fibrosis were analysed by logistic regression and decision-tree analyses. RESULTS: Liver stiffness was higher in MAFLD compared to NAFLD (7.7 vs 6.8 kPa, P = .0010). In logistic regression, MAFLD (OR 4.401; 95% CI 2.144-10.629; P < .0001), alcohol intake (OR 1.761; 95% CI 1.081-2.853; P = .0234), and NAFLD (OR 1.721; 95%CI 1.009-2.951; P = .0463) were independently associated with significant fibrosis. By decision-tree analysis, MAFLD, but not NAFLD or alcohol consumption was the initial classifier for significant fibrosis. The sensitivity for detecting significant fibrosis was higher for MAFLD than NAFLD (93.9% vs 73.0%). In patients with MAFLD, even mild alcohol intake was associated with an increase in the prevalence of significant fibrosis (25.0% vs 15.5%; P = .0181). CONCLUSIONS: The MAFLD definition better identifies a group with fatty liver and significant fibrosis evaluated by non-invasive tests. Moreover, in patients with MAFLD, even mild alcohol consumption is associated with worsening of hepatic fibrosis measures.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Metabolic-associated fatty liver disease (MAFLD) is the most common finding in patients with TS.
“Metabolic-associated fatty liver disease (MAFLD), is the most common finding in patients with TS.717”
From Clinical practice guidelines for the care of girls and women with Turner syndrome. (2024) · cites this paper as [717]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961 · see citing works
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · see citing works
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · see citing works
Self-citationSterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021 · cited 4× · see citing works
“ALT (U/L) 19 (14-29) 4-122 22 (16-33) 4-188 .”
InfluentialMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854 · see citing works
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836 · see citing works
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763 · see citing works
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472 · see citing works
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406 · see citing works
Griswold, M. G., Fullman, N., Hawley, C., Arian, N., Zimsen, S. R. M., Tymeson, H. D., Venkateswaran, V., Tapp, A. D., Forouzanfar, M. H., Salama, J. S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31310-2 · Cited by 3,524 · see citing works
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286 · see citing works
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,198 · see citing works
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,054 · see citing works
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890 · see citing works
Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease
Castera, L., Friedrich-Rust, M., & Loomba, R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.036 · Cited by 1,494 · see citing works
Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A.-M., Zethelius, B., Miftaraj, M., McGuire, D. K., Rosengren, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800256 · Cited by 1,475 · see citing works
Ascha, M. S., Hanouneh, I. A., Lopez, R., Tamimi, T. A.-R., Feldstein, A. F., & Zein, N. N. (2010) · Hepatology · doi:10.1002/hep.23527 · Cited by 1,296 · see citing works
Dietrich, C., Bamber, J. C., Berzigotti, A., Bota, S. I., Cantisani, V., Castéra, L., Cosgrove, D. O., Ferraioli, G., Friedrich‐Rust, M., Gilja, O. H., et al. (2017) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/s-0043-103952 · Cited by 1,016 · see citing works
Ye, Q., Zou, B., Yeo, Y. H., Li, J., Huang, D. Q., Wu, Y., Yang, H., Liu, C., Kam, L. Y., Tan, X. X. E., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30077-7 · Cited by 925 · see citing works
Vilar-Gomez, E., Calzadilla-Bertot, L., Wai-Sun Wong, V., Castellanos, M., Aller-de la Fuente, R., Metwally, M., Eslam, M., Gonzalez-Fabian, L., Alvarez-Quiñones Sanz, M., Conde-Martin, A. F., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.034 · Cited by 806 · see citing works
Williams, B., Mancia, G., Spiering, W., Rosei, E. A., Azizi, M., Burnier, M., Clement, D. L., Coca, A., SIMONE, G. D., Dominiczak, A. F., et al. (2018) · Blood Pressure · doi:10.1080/08037051.2018.1527177 · Cited by 710 · see citing works
Comparison of MAFLD and NAFLD diagnostic criteria in real world
Lin, S., Huang, J., Wang, M.-F., Kumar, R., Liu, Y., Liu, S., Wu, Y., Wang, X., & Zhu, Y. (2020) · Liver International · doi:10.1111/liv.14548 · Cited by 518 · see citing works
Dunn, W., Sanyal, A. J., Brunt, E. M., Ünalp–Arida, A., Donohue, M., McCullough, A. J., & Schwimmer, J. B. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.03.024 · Cited by 276 · see citing works
Ekstedt, M., Franzén, L., Holmqvist, M., Bendtsen, P., Mathiesen, U., Bodemar, G., Ekstedt, M., Franzén, L., Holmqvist, M., Bendtsen, P., et al. (2008) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520802555991 · Cited by 207 · see citing works
Chang, Y., Cho, Y. K., Kim, Y., Sung, E., Ahn, J., Jung, H., Yun, K. E., Shin, H. C., & Ryu, S. (2018) · Hepatology · doi:10.1002/hep.30170 · Cited by 162 · see citing works
Kwon, H. K., Greenson, J. K., & Conjeevaram, H. S. (2013) · Liver International · doi:10.1111/liv.12230 · Cited by 99 · see citing works
Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?
Ratziu, V., & Friedman, S. L. (2023) · Gastroenterology · doi:10.1053/j.gastro.2020.05.046 · Cited by 88 · see citing works
FibroGENE: A gene-based model for staging liver fibrosis
Eslam, M., Hashem, A. M., Romero‐Gómez, M., Berg, T., Dore, G. J., Mangia, A., Chan, H. L., Irving, W. L., Sheridan, D. A., Abate, M. L., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.008 · Cited by 75 · see citing works
Chang, Y., Ryu, S., Kim, Y., Cho, Y. K., Sung, E., Kim, H., Ahn, J., Jung, H. S., Yun, K. E., Kim, S., et al. (2019) · Hepatology · doi:10.1002/hep.30867 · Cited by 73 · see citing works
Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health
Eslam, M., Fan, J., & Méndez‐Sánchez, N. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30090-x · Cited by 68 · see citing works
Åberg, F., Färkkilä, M., & Männistö, V. (2020) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14271 · Cited by 63 · see citing works
Williams, B., Mancia, G., Spiering, W., Rosei, E., Azizi, M., & Burnier, M. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002026 · Cited by 57 · see citing works
Kim, Y., Chang, Y., Cho, Y. K., Ahn, J., Shin, H. C., & Ryu, S. (2019) · Liver International · doi:10.1111/liv.14184 · Cited by 46 · see citing works
Yamamura, S., Kawaguchi, T., Nakano, D., Tomiyasu, Y., Yoshinaga, S., Doi, Y., Takahashi, H., Anzai, K., Eguchi, Y., Torimura, T., et al. (2019) · Hepatology Research · doi:10.1111/hepr.13436 · Cited by 36 · see citing works
Yamada, S., Kawaguchi, A., Kawaguchi, T., Fukushima, N., Kuromatsu, R., Sumie, S., Takata, A., Nakano, M., Satani, M., Tonan, T., et al. (2013) · Hepatology Research · doi:10.1111/hepr.12192 · Cited by 35 · see citing works
Kim, D., Kim, W. K., Joo, S. K., Han, J., Kim, J. H., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01628-z · Cited by 28 · see citing works
Wong, R. J., Tran, T. T., Kaufman, H. W., Niles, J. K., & Gish, R. G. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220612 · Cited by 23 · see citing works
Flagged first, then by citations
1 of the 38 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Targher, G., Tilg, H., & Byrne, C. D. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00020-0 · Cited by 586 · see citing works
Lee, H., Lee, Y., Kim, S. U., & Kim, H. C. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.12.022 · Cited by 463 · see citing works
MAFLD: How is it different from NAFLD?
Gofton, C., Upendran, Y., Zheng, M., & George, J. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0367 · Cited by 436 · see citing works
Chan, K. E., Koh, T. J. L., Tang, A. S. P., Quek, J., Yong, J. N., Tay, P. W. L., Tan, D. J. H., Lim, W. H., Lin, S. Y., Huang, D. Q., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac321 · Cited by 323 · see citing works
Eslam, M., Alkhouri, N., Vajro, P., Baumann, U., Weiss, R., Socha, P., Marcus, C., Lee, W. S., Kelly, D. A., Porta, G., et al. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00183-7 · Cited by 281 · see citing works
Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
Lee, H., Lee, H. A., Kim, E.-J., Kim, H. Y., Kim, H. C., Ahn, S. H., Lee, H., & Kim, S. U. (2023) · Gut · doi:10.1136/gutjnl-2023-331003 · Cited by 270 · see citing works
Non-alcoholic fatty liver disease: Definition and subtypes
Han, S. K., Baik, S. K., & Kim, M. Y. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0424 · Cited by 263 · see citing works
Global multi-stakeholder endorsement of the MAFLD definition
Méndez-Sánchez, N., Bugianesi, E., Gish, R. G., Lammert, F., Tilg, H., Nguyen, M. H., Sarin, S. K., Fabrellas, N., Zelber-Sagi, S., Fan, J.-G., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00062-0 · Cited by 248 · see citing works
Lim, G. E. H., Tang, A. S. P., Ng, C. H., Chin, Y. H., Lim, W. H., Tan, D. J. H., Yong, J. N., Xiao, J., Lee, C. W.-M., Chan, M. Y., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.11.038 · Cited by 248 · see citing works
Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight
Eslam, M., El‐Serag, H. B., Francque, S., Sarin, S. K., Wei, L., Bugianesi, E., & George, J. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00635-5 · Cited by 246 · see citing works
Liu, J., Ayada, I., Zhang, X., Wang, L., Yang, L., Wen, T., Ma, Z., Bruno, M. J., de Knegt, R. J., Cao, W., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.02.030 · Cited by 243 · see citing works
Pipitone, R. M., Ciccioli, C., Infantino, G., Mantia, C. L., Parisi, S., Tulone, A., Pennisi, G., Grimaudo, S., & Petta, S. (2023) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221145549 · Cited by 239 · see citing works
Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver
Kaya, E., & Yilmaz, Y. N. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00178 · Cited by 230 · see citing works
Association of metabolic dysfunction-associated fatty liver disease with kidney disease
Wang, T.-Y., Wang, R.-F., Bu, Z.-Y., Targher, G., Byrne, C. D., Sun, D.-Q., & Zheng, M.-H. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00519-y · Cited by 221 · see citing works
Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD
Nguyen, V. H., Le, M. H., Cheung, R. C., & Nguyen, M. H. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.05.029 · Cited by 217 · see citing works
Clinical practice guidelines for the care of girls and women with Turner syndrome.
Gravholt, C. H., Andersen, N. H., Christin-Maitre, S., Davis, S. M., Duijnhouwer, A., Gawlik, A., Maciel-Guerra, A. T., Gutmark-Little, I., Fleischer, K., Hong, D., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae050 · Cited by 224 · see citing works
Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease
Lim, S. K., Kim, J., & Targher, G. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.04.008 · Cited by 216 · see citing works
Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
Grander, C., Grabherr, F., & Tilg, H. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad095 · Cited by 216 · see citing works
Ciardullo, S., & Perseghin, G. (2021) · Liver International · doi:10.1111/liv.14828 · Cited by 191 · see citing works
Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease?
Younossi, Z. M., Paik, J. M., Shabeeb, R. Q. A., Golabi, P., Younossi, I. M., & Henry, L. L. (2022) · Hepatology · doi:10.1002/hep.32499 · Cited by 184 · see citing works
Liang, Y., Chen, H., Liu, Y., Hou, X., Wei, L., Bao, Y., Yang, C., Zong, G., Wu, J., & Jia, W. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab641 · Cited by 182 · see citing works
Tsutsumi, T., Eslam, M., Kawaguchi, T., Yamamura, S., Kawaguchi, A., Nakano, D., Koseki, M., Yoshinaga, S., Takahashi, H., Anzai, K., et al. (2021) · Hepatology Research · doi:10.1111/hepr.13685 · Cited by 170 · see citing works
Méndez‐Sánchez, N., Arrese, M. A., Gadano, A. C., de Oliveira, C. P. M. S., Fassio, E., Arab, J. P., Chávez-Tapia, N. C., Dirchwolf, M., Torre, A., Ridruejo, E., et al. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30340-x · Cited by 148 · see citing works
van Kleef, L. A., Choi, H. S. J., Brouwer, W. P., Hansen, B. E., Patel, K., de Man, R. A., Janssen, H. L. A., de Knegt, R. J., & Sonneveld, M. J. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100350 · Cited by 117 · see citing works
The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease
Nan, Y., An, J., Bao, J., Chen, H., Chen, Y., Ding, H., Dou, X., Duan, Z., Fan, J., Gao, Y., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.003 · Cited by 116 · see citing works
MAFLD: Renovation of clinical practice and disease awareness of fatty liver
Kawaguchi, T., Tsutsumi, T., Nakano, D., & Torimura, T. (2021) · Hepatology Research · doi:10.1111/hepr.13706 · Cited by 117 · see citing works
Habibullah, M., Jemmieh, K., Ouda, A., Haider, M. Z., Malki, M. I., & Elzouki, A.-N. Y. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1291501 · Cited by 112 · see citing works
Ayada, I., van Kleef, L. A., Alferink, L. J. M., Li, P., de Knegt, R. J., & Pan, Q. (2021) · Liver International · doi:10.1111/liv.15139 · Cited by 107 · see citing works
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Arrese, M. A., Arab, J. P., Francisco Barrera, M., Kaufmann, B. K., Valenti, L. V. C., & Feldstein, A. E. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1730927 · Cited by 104 · see citing works
Huang, S., & Liu, C. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0422 · Cited by 102 · see citing works
Eslam, M., Ahmed, A., Després, J., Jha, V., Halford, J. C. G., Chieh, J. T. W., Harris, D. C. H., Nangaku, M., Colagiuri, S., Targher, G., et al. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00132-1 · Cited by 101 · see citing works
The NAFLD‐MAFLD debate: Eminence vs evidence
Fouad, Y. M., Elwakil, R., Elsahhar, M., Said, E., Bazeed, S. E. S., Gomaa, A., Hashim, A. H., Kamal, E., Mehrez, M. I., & Attia, D. I. (2020) · Liver International · doi:10.1111/liv.14739 · Cited by 97 · see citing works
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Kawaguchi, T., Tsutsumi, T., Nakano, D., Eslam, M., George, J., & Torimura, T. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0310 · Cited by 92 · see citing works
Sun, D., Targher, G., Byrne, C. D., Wheeler, D. C., Wong, V. W., Fan, J., Tilg, H., Yuan, W., Wanner, C., Gao, X., et al. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-22-421 · Cited by 90 · see citing works
van Kleef, L. A., Ayada, I., Alferink, L. J. M., Pan, Q., & de Knegt, R. J. (2021) · Hepatology · doi:10.1002/hep.32131 · Cited by 90 · see citing works
Ciardullo, S., Muraca, E., Vergani, M., Invernizzi, P., & Perseghin, G. (2023) · Gastroenterology report · doi:10.1093/gastro/goae029 · Cited by 90 · see citing works
Kang, S. H., Cho, Y., Jeong, S. W., Kim, S. U., Lee, J., & On behalf of Korean NAFLD Study Group (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0067 · Cited by 88 · see citing works
Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification?
Ramírez-Mejía, M. M., Jiménez-Gutiérrez, C., Eslam, M., George, J., & Méndez‐Sánchez, N. (2023) · Hepatology International · doi:10.1007/s12072-023-10620-y · Cited by 87 · see citing works
PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date
Cherubini, A., Casirati, E., Tomasi, M., & Valenti, L. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2018418 · Cited by 79 · see citing works
Metabolic dysfunction-associated fatty liver disease: a year in review
Alharthi, J., Gastaldelli, A., Cua, I. H., Ghazinian, H., & Eslam, M. (2022) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000823 · Cited by 76 · see citing works
Cól, J. P. D., de Lima, E. P., Pompeu, F. M., Araújo, A. C., Goulart, R. D. Á., Bechara, M. D., Laurindo, L. F., Méndez‐Sánchez, N., & Barbalho, S. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073694 · Cited by 76 · see citing works
Moon, J. S., Hong, J. H., Jung, Y. J., Ferrannini, E., Nauck, M. A., & Lim, S. K. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.03.005 · Cited by 75 · see citing works
Metabolic Reprogramming of Liver Fibrosis
Delgado, M. E., Cárdenas, B., Farran, N., & Fernández, M. (2021) · Cells · doi:10.3390/cells10123604 · Cited by 73 · see citing works
Artificial intelligence in prediction of non‐alcoholic fatty liver disease and fibrosis
Wong, G. L., Yuen, P. C., Ma, A. J., Chan, A. W. H., Leung, H. H. W., & Wong, V. W. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15385 · Cited by 71 · see citing works
van Kleef, L. A., de Knegt, R. J., & Brouwer, W. P. (2022) · Hepatology · doi:10.1002/hep.32642 · Cited by 71 · see citing works
Dongiovanni, P., Paolini, E., Corsini, A., Sirtori, C. R., & Ruscica, M. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13519 · Cited by 70 · see citing works
Moon, J. H., Kim, W. K., Koo, B. K., & Cho, N. H. (2021) · Gut and Liver · doi:10.5009/gnl210167 · Cited by 67 · see citing works
Yuan, Q., Wang, H., Gao, P., Chen, W., Lv, M., Bai, S., & Wu, J. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19042096 · Cited by 67 · see citing works
Tauil, R. B., Golono, P. T., de Lima, E. P., Goulart, R. D. Á., Guiguer, É. L., Bechara, M. D., Nicolau, C. C. T., Yanaguizawa, J. L., Fiorini, A. M. R., Méndez‐Sánchez, N., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17101354 · Cited by 73 · see citing works
Clinical utility of the MAFLD definition
Zheng, K. I., Sun, D., Jin, Y., Zhu, P., & Zheng, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.12.016 · Cited by 64 · see citing works
Nutritional Support for Alcoholic Liver Disease
Tadokoro, T., Morishita, A., Himoto, T., & Masaki, T. (2023) · Nutrients · doi:10.3390/nu15061360 · Cited by 66 · see citing works
Beygi, M., Ahi, S., Zolghadri, S., & Stanek, A. (2024) · Nutrients · doi:10.3390/nu16142220 · Cited by 64 · see citing works
Yilmaz, Y. N., Byrne, C. D., & Musso, G. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1860019 · Cited by 58 · see citing works
MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease
Huang, J., Ou, W., Wang, M.-F., Singh, M., Liu, Y., Liu, S., Wu, Y., Zhu, Y., Kumar, R., & Lin, S. (2021) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s285880 · Cited by 58 · see citing works
Frankowski, R., Kobierecki, M., Wittczak, A., Różycka-Kosmalska, M., Pietras, T., Sipowicz, K., & Kosmalski, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119677 · Cited by 58 · see citing works
Kim, H., Lee, C. J., Ahn, S. H., Lee, K. S., Lee, B. K., Baik, S. J., Kim, S. U., & Lee, J. I. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07508-6 · Cited by 57 · see citing works
Autophagy Dysregulation in Metabolic Associated Fatty Liver Disease: A New Therapeutic Target
Chen, C., & Lin, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710055 · Cited by 57 · see citing works
Qiu, K., Zhao, Q., Wang, J., Qi, G., Wu, S., & Zhang, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031458 · Cited by 56 · see citing works
Fukunaga, S., Nakano, D., Kawaguchi, T., Eslam, M., Ouchi, A., Nagata, T., Kuroki, H., Kawata, H., Hirohiko, A. B. E., Nouno, R., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115462 · Cited by 56 · see citing works
Lee, H., Lee, H. W., Kim, S. U., & Kim, H. C. (2022) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000435 · Cited by 55 · see citing works
Chun, H. S., Kim, M. N., Lee, J. S., Lee, H. W., Kim, B. K., Park, J. Y., Kim, D. Y., Ahn, S. H., & Kim, S. U. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12754 · Cited by 54 · see citing works
Han, A. L., & Lee, H. K. (2022) · Metabolites · doi:10.3390/metabo12070664 · Cited by 52 · see citing works
Lee, S. M., Jung, Y. M., Choi, E. S., Kwak, S. H., Koo, J. N., Oh, I. H., Kim, B. J., Kim, S. M., Kim, S. Y., Kim, G. M., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.11.007 · Cited by 51 · see citing works
Lonardo, A., Singal, A. K., Osna, N. A., & Kharbanda, K. K. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.14 · Cited by 49 · see citing works
Fouad, Y. M., Esmat, G., Elwakil, R., Zakaria, S., Yosry, A., Waked, I. A., El-Razky, M., Doss, W. H., El‐Serafy, M., Mostafa, E., et al. (2022) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_357_21 · Cited by 48 · see citing works
From NAFLD to MAFLD: Nurse and allied health perspective
Clayton, M., Fabrellas, N., Luo, J., Alghamdi, M., Hafez, A., Qadiri, T. A., Owise, N., & Attia, D. I. (2021) · Liver International · doi:10.1111/liv.14788 · Cited by 46 · see citing works
MAFLD: an optimal framework for understanding liver cancer phenotypes
Crane, H., Gofton, C., Sharma, A., & George, J. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02021-7 · Cited by 45 · see citing works
Yu, C., Wang, M., Zheng, S., Xia, M., Yang, H., Zhang, D., Yin, C., Cheng, N., & Bai, Y. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00089 · Cited by 45 · see citing works
Detangling the interrelations between MAFLD, insulin resistance, and key hormones
Pal, S. C., Eslam, M., & Méndez‐Sánchez, N. (2022) · HORMONES · doi:10.1007/s42000-022-00391-w · Cited by 44 · see citing works
Fouad, Y. M., Lazarus, J. V., Negro, F., Peck‐Radosavljevic, M., Sarin, S. K., Ferenci, P., Esmat, G., Ghazinian, H., Nakajima, A., Silva, M., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16346 · Cited by 44 · see citing works
Changing clinical management of NAFLD in Asia
Nakatsuka, T., Tateishi, R., & Koike, K. (2021) · Liver International · doi:10.1111/liv.15046 · Cited by 44 · see citing works
Kim, M., Yoon, E. L., Cho, S., Lee, C., Kang, B., Park, H., Jun, D. W., & Nah, E. (2022) · Liver International · doi:10.1111/liv.15259 · Cited by 43 · see citing works
Abenavoli, L., Scarlata, G. G. M., Scarpellini, E., Boccuto, L., Spagnuolo, R., Tilocca, B., Roncada, P., & Luzza, F. (2023) · Medicina · doi:10.3390/medicina59030594 · Cited by 44 · see citing works
Metabolic dysfunction: The silenced connection with fatty liver disease
Ramírez-Mejía, M. M., Qi, X., Abenavoli, L., Romero‐Gómez, M., Eslam, M., & Méndez‐Sánchez, N. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101138 · Cited by 41 · see citing works
From NAFLD to MASLD: When metabolic comorbidity matters
Hong, S., Sun, L., Hao, Y., Li, P., Zhou, Y., Liang, X., Hu, J., & Wei, H. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101281 · Cited by 41 · see citing works
Metabolic and alcohol-associated liver disease (MetALD): a representation of duality
Leal-Lassalle, H., Estévez‐Vázquez, O., Cubero, F. J., & Nevzorova, Y. A. (2025) · npj gut and liver. · doi:10.1038/s44355-024-00014-8 · Cited by 41 · see citing works
On the Proposed Definition of Metabolic-Associated Fatty Liver Disease
Wong, V. W., & Kanwal, F. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.01.017 · Cited by 42 · see citing works
MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease
Pan, Z., Derbala, M. F. M., Al-Naamani, K. M., Ghazinian, H., Fan, J., & Eslam, M. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101512 · Cited by 40 · see citing works
Kamada, Y., Takahashi, H., Shimizu, M., Kawaguchi, T., Sumida, Y., Fujii, H., Seko, Y., Fukunishi, S., Tokushige, K., Nakajima, A., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01833-9 · Cited by 40 · see citing works
Tang, L., Ma, H., Eslam, M., Wong, G. L., Zhu, P., Chen, S., Leeming, D. J., Karsdal, M. A., Li, G., Huang, O., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154958 · Cited by 40 · see citing works
Zhu, C., Huang, D., Ma, H., Qian, C., You, H., Bu, L., & Qu, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.848937 · Cited by 38 · see citing works
Wan, H., Yu, G., Xu, S., Chen, X., Jiang, Y., Duan, H., Xu, L., Ma, Q., Wang, D., Liang, Y., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad186 · Cited by 37 · see citing works
Zhao, J., Zhao, Y., Hu, Y., & Peng, J. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00276-7 · Cited by 37 · see citing works
Suzuki, K., Tamaki, N., Kurosaki, M., Takahashi, Y., Yamazaki, Y., Uchihara, N., Tanaka, Y., Miyamoto, H., Yamada, M., Keitoku, T., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14011 · Cited by 36 · see citing works
What’s New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
Kosmalski, M., Frankowski, R., Ziółkowska, S., Różycka-Kosmalska, M., & Pietras, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051852 · Cited by 37 · see citing works
Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
Kim, K., Hong, S., Ahn, H. Y., & Park, C. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0327 · Cited by 35 · see citing works
Yet more evidence that MAFLD is more than a name change
Eslam, M., Ratziu, V., & George, J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.12.025 · Cited by 35 · see citing works
Cheng, Y., Wang, C., & Kao, J. (2022) · Hepatology International · doi:10.1007/s12072-022-10449-x · Cited by 34 · see citing works
Zhang, H., Targher, G., Byrne, C. D., Kim, S., Wong, V. W.-S., Valenti, L., Glickman, M., Ponce, J., Mantzoros, C. S., Crespo, J., et al. (2024) · Hepatology International · doi:10.1007/s12072-024-10702-5 · Cited by 34 · see citing works
NAFLD VS MAFLD. The evidence-based debate has come. Time to change?
García‐Compeán, D., & Jiménez-Rodríguez, A. R. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100765 · Cited by 33 · see citing works
Kaya, E., & Yilmaz, Y. N. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221139650 · Cited by 36 · see citing works
Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change
Wong, V. W., & Lazarus, J. V. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.020 · Cited by 33 · see citing works
Liu, H., Cao, Y., Jin, J., Guo, Y., Zhu, C., Wu, N., Gao, Y., Xu, R., Dong, Q., Zheng, M., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10252-0 · Cited by 32 · see citing works
Chen, Y., Yang, C., Chung, C., Ho, C., Chen, W., & Chien, W. (2022) · Hepatology International · doi:10.1007/s12072-021-10281-9 · Cited by 32 · see citing works
NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
Portincasa, P. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03203-0 · Cited by 33 · see citing works
Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets
Santos-Laso, A., Gutiérrez-Larrañaga, M., Alonso-Peña, M., Medina, J. M., Iruzubieta, P., Arias-Loste, M., López-Hoyos, M., & Crespo, J. (2021) · Biomedicines · doi:10.3390/biomedicines10010046 · Cited by 31 · see citing works
Yuan, X., Wang, X., Wu, S., Chen, S., Wang, Y., Wang, J., Lu, Y., Sun, Y., Fu, Q., & Li, W. (2022) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-546 · Cited by 31 · see citing works
Shimose, S., Hiraoka, A., Gardini, A. C., Tsutsumi, T., Nakano, D., Iwamoto, H., Tada, F., Rimini, M., Tanaka, M., Torimura, T., et al. (2022) · Hepatology Research · doi:10.1111/hepr.13843 · Cited by 31 · see citing works
Kamada, Y., Nakamura, T., Isobe, S., Hosono, K., Suama, Y., Ohtakaki, Y., Nauchi, A., Yasuda, N., Mitsuta, S., Miura, K., et al. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01932-1 · Cited by 31 · see citing works
Mantovani, A. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.05.014 · Cited by 30 · see citing works
- Authors
- Yamamura, S., Eslam, M., Kawaguchi, T., Tsutsumi, T., Nakano, D., Yoshinaga, S., Takahashi, H., Anzai, K., George, J., & Torimura, T.
- Affiliations
- Kurume University (JP)
- The University of Sydney (AU)
- Medical Examination Section Medical Examination Part Facilities Public Utility Foundation Saga Prefectural Health Promotion Foundation Saga Japan
- Saga University (JP)
- Corresponding author
- Yamamura, Sakura
- Eslam, Mohammed
- ORCID
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2020-11-30
- Volume
- 40
- Issue
- 12
- Pages
- 3018-3030
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W3089758949
- Cited by
- 401
- References
- 38
- Citations by year
- 2026: 10 · 2025: 33 · 2024: 85 · 2023: 96 · 2022: 84 · 2021: 84 · 2020: 6 · 2014: 1
- FWCI
- 48.37
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Liver International (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (acceptedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- Funders
- Japan Agency for Medical Research and Development (JP20fk0210040)
- Research and Development
- Medical Foundation (APP1107178, APP1108422)
- University of Sydney
- Medical Research Council
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- metabolic-associated fatty liver disease, non-alcoholic fatty liver disease, liver fibrosis, diagnostic accuracy, liver stiffness, shear wave elastography, FIB-4, hepatic steatosis, noninvasive fibrosis assessment
- MeSH terms
- Humans, Liver Cirrhosis, Middle Aged, Prevalence, Logistic Models, Elasticity Imaging Techniques, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
